bluebird bio

bluebird bio is developing next-generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. It has two clinical stage products in development for childhood cerebral adrenoleukodystrophy and betathalassemia/sickle cell disease, a preclinical oncology programme in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform.